|Slideshows|May 25, 2017

4 Myths About Assisted Outpatient Treatment

Author(s)E. Fuller Torrey, MD, John D. Snook, JD

After lounging on the doorstep of respectability for the past decade, assisted outpatient treatment is here to stay. But some still balk at the notion.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

NCCHC 2025 Virtual Winter Conference on Correctional Health Care Offers CE and Remote Education on Critical Topics

ByKim Sterling

November 4th 2025

Correctional Psychiatry Enters a New Era: NCCHC Releases 2026 Mental Health Standards

ByKim Sterling

November 3rd 2025

Journeys Through Forensic Psychiatry, With Jessie Hill, MD, and Frank Clark, MD

ByFrank A. Clark, MD,Jessie Hill, MD

October 24th 2025

Reflections on Developments in Correctional Psychiatry, with Tony Tamburello, MD

ByTony Tamburello, MD

October 17th 2025

Female Offenders: Patterns, Risk, and Assessment

ByAnne-Marie Hathaway, DO

April 7th 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

4 Myths About Assisted Outpatient Treatment

Newsletter

Related Content

NCCHC 2025 Virtual Winter Conference on Correctional Health Care Offers CE and Remote Education on Critical Topics

Correctional Psychiatry Enters a New Era: NCCHC Releases 2026 Mental Health Standards

Journeys Through Forensic Psychiatry, With Jessie Hill, MD, and Frank Clark, MD

Reflections on Developments in Correctional Psychiatry, with Tony Tamburello, MD

Female Offenders: Patterns, Risk, and Assessment

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State